NEW YORK CITY (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said Thursday that it has separately filed suit in United States District Court for the District of Delaware against Pfizer Inc. and
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):Earnings: -$258.46 million in Q4 vs. $243.54 million in the same period last year. EPS: -$2.16
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc.'s (ALNY) phase III trial of investigational RNAi therapeutic Vutrisiran in patients with hATTR amyloidosis with polyneuropathy has met all secondary
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) said the HELIOS-A phase 3 study of vutrisiran met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis
- Company to Host Conference Call January 21st at 8:30 am ET to Discuss Results - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company